In 2024 , EssilorLuxottica actively lead the global myopia conversation at key scientific events, presenting our five-year clinical trial results for Essilor Stellest lenses as well as expertise on holistic myopia management solutions, advances in clinical refraction and new research on highly aspherical lenslets (HAL) plus innovations and future directions for myopia management.
Advancing Myopia Management on a Global Scale
Reaffirming our global leadership in myopia management, EssilorLuxottica continues to make significant strides to tackle this rapidly growing visual impairment and promote better eye health for future generations.
"We are proud to have had a meaningful year of progress in addressing myopia, with important steps forward. Notably, we shared our latest research to help lay the groundwork for long-term, safe and effective myopia solutions."
OLGA PRENAT, Head of Medical and Professional Affairs and GMAC Board Chair
We also marked a major milestone with a ‘Breakthrough Devices’ designation granted to SightGlass Vision – EssilorLuxottica’s myopia management joint venture with CooperCompanies – by the US Food and Drug Administration for our Diffusion Optics Technology (DOT) spectacle lenses designed to slow myopia progression in children.
EssilorLuxottica is dedicated to driving myopia awareness and education through collaborations with our global partners, including the International Myopia Institute (IMI), Myopia Profile, the Global Myopia Awareness Coalition, the World Society of Paediatric Ophthalmology & Strabismus and the Review of Myopia Management.
We were also a Platinum sponsor during Myopia Action Month 2024 and participated in the inaugural edition of the Euretina Special Focus Meeting, which advances evidence-based science on myopia. In addition, the Eyestar Mission educational program, which helps fight myopia with a positive approach by empowering children to take ownership of their vision care, was successfully delivered and received very positive feedback in a number of countries.
Through our Leonardo learning platform, we continued to support eyecare professionals (ECPs) with novel resources on myopia management based on evidence and research, including a new three-module course and a video covering the latest scientific highlights for Essilor Stellest lenses.
Essilor Stellest Lenses: Continued Efficacy & Performance
Announced in 2024, new findings from our five-year clinical follow-up study of Essilor Stellest lenses demonstrate conclusive evidence of their efficacy in slowing down myopia progression in children in the fifth year.
